Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
about
Fluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsTherapeutic and diagnostic challenges for frontotemporal dementiaImproving and accelerating drug development for nervous system disordersProfile of gantenerumab and its potential in the treatment of Alzheimer's diseaseHarnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and ChallengesGenetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunitiesLongitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer's disease.Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimer's and Family).The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Future Directions in Imaging Neurodegeneration.Mild to moderate Alzheimer dementia with insufficient neuropathological changes.Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform NetworkPrediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data.Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity.Contemplating Alzheimer's disease and the contribution of white matter hyperintensities.Advances in the prevention of Alzheimer's Disease.Laminar specific detection of APP induced neurodegeneration and recovery using MEMRI in an olfactory based Alzheimer's disease mouse modelAlzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases.Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change?What does complement do in Alzheimer's disease? Old molecules with new insights.Therapy and clinical trials in frontotemporal dementia: past, present, and future.Repetitive head impact exposure and later-life plasma total tau in former National Football League players.The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?Harnessing the immune system for treatment and detection of tau pathology.Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target.Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.Alzheimer's disease genetics: from the bench to the clinic.Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.Targeted delivery of protein and gene medicines through the blood-brain barrier.Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?Dementia risk and prevention by targeting modifiable vascular risk factors.
P2860
Q26784569-805450AA-204C-40FF-B9FF-466FD94FFA69Q26998919-E6F95DE7-5FBA-40E8-AFF3-2D5609FB1558Q27008349-9B540630-3E00-4F6E-95A6-D5712C46ADDDQ27027675-802ED2ED-4D63-4F89-A222-378912F500D9Q28072061-128D506F-6BF6-446F-BEEB-E983D89D34AFQ28086879-28026FA8-542C-4F41-BDA8-7754A1E025BFQ30587067-C72F6314-59F1-41C3-91E9-CD973295A622Q30996739-0BDA1C5A-152E-42E9-B966-A159BB32FED9Q31147579-52266CB7-3D8A-45DB-85F8-2AAA53C59733Q31162702-DA672A68-BC90-4CD1-923B-D63F71B53867Q33592693-88C8052A-811F-4469-9121-99AC1C4CCDC2Q33613942-6F6585AC-3B05-41CD-8951-F34416F375D2Q33816135-B81C2277-CB50-48E4-B08C-3B4B9E6C31C5Q34630570-85D39DD3-3990-4F55-8807-3294AC587F7DQ35031724-B0513C24-D2B3-4A3A-BF46-612000FC2E1EQ35659387-B2C3BFC6-B272-40AD-8266-1DC6893E32BBQ36519498-16E9013F-37B8-43F3-8DF2-23685077A37AQ36574825-0434A3BE-FC2D-4732-96B0-C52A484A6957Q36588166-DF60D7E4-8374-46D4-81D4-FA5CDF42707EQ36801792-46BB4DAA-2EA3-433E-9C21-7BF59DE93F44Q36885357-3DA41FE6-1796-4B4C-B584-595B75B24944Q36904682-94095A76-A777-489D-B20F-1617892D9412Q36933700-C416B5F5-BD58-44C4-9ED2-BD4716247673Q37292848-992BAF17-9EA6-4F11-AEB2-AD0044C91393Q37368120-6B058B2F-DE7A-47FE-8EF1-9A82DB9B2371Q37566888-DDDE4E3B-2AD0-4856-9C13-585484198F38Q37645272-F00DDE1E-BDB0-4825-8D5A-A6775DCAE091Q37656554-4B0CBFAD-AF80-4951-9481-5BE7659DC698Q37690649-0235EBAF-E485-4AE7-8DDF-FB45A68A3BAAQ37690944-1B97FA84-8307-4EA4-B927-6035891710CFQ38140071-D52F0581-B777-4E67-9D70-2BA13C02EB1CQ38194049-068D76DB-B5DF-4913-A963-136FCDF410DBQ38202910-7CD796A4-EE43-4A59-AD1C-0EC1556DA49AQ38208461-E6E12620-7DB9-46D5-A604-14C4A8CDC7D9Q38225911-90A16E27-9570-468F-A19A-025F3D752DA4Q38299414-9DE7C882-F6E9-45F7-A8A0-7E8CF88A0331Q38344088-892F653E-DE8C-479B-9E21-E9E5E4852ECCQ38351122-CCD4EF20-2A58-41D2-9BB6-EB2E1E6C1FE7Q38592069-36C945B2-342F-43F5-9AFA-74142907A258Q38653373-4FF9FF7D-CB1A-4705-8752-CF2407FC035C
P2860
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Designing drug trials for Alzh ...... rom the EU/US/CTAD Task Force.
@en
Designing drug trials for Alzh ...... rom the EU/US/CTAD Task Force.
@nl
type
label
Designing drug trials for Alzh ...... rom the EU/US/CTAD Task Force.
@en
Designing drug trials for Alzh ...... rom the EU/US/CTAD Task Force.
@nl
prefLabel
Designing drug trials for Alzh ...... rom the EU/US/CTAD Task Force.
@en
Designing drug trials for Alzh ...... rom the EU/US/CTAD Task Force.
@nl
P2093
P50
P1476
Designing drug trials for Alzh ...... rom the EU/US/CTAD Task Force.
@en
P2093
Bruno Dubois
EU/US/CTAD Task Force Members
Eric Siemers
Ezio Giacobini
Gordon K Wilcock
H Robert Brashear
Jacques Touchon
Jesse Cedarbaum
Karl Broich
Lon S Schneider
P304
P356
10.1016/J.JALZ.2013.03.007
P50
P577
2013-07-01T00:00:00Z